A Phase I Multiple Ascending Dose Study of ASLAN002 (BMS 777607) in Subjects With Advanced or Metastatic Solid Tumours

Trial Profile

A Phase I Multiple Ascending Dose Study of ASLAN002 (BMS 777607) in Subjects With Advanced or Metastatic Solid Tumours

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Feb 2017

At a glance

  • Drugs BMS 777607 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors ASLAN Pharmaceuticals
  • Most Recent Events

    • 15 Feb 2017 Results published in an ASLAN Pharmaceuticals media release.
    • 15 Feb 2017 According to an ASLAN Pharmaceuticals media release, new data from this phase 1 study of ASLAN002 (BMS777607) published in Science Translational Medicine journal.
    • 23 Jan 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top